TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- In The News: CAR-T Cells for HIV
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the March 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
Category: Cure research
-
For August 2025, there were eight updates to the TAG listing. New Additions A study sponsored by the ANRS RHIVIERA project in France plans to investigate the JAK1/JAK2 Inhibitor baricitinib and the mTOR Inhibitor sirolimus in people who started antiretroviral therapy (ART) soon after HIV acquisition. Baricitinib is also being tested in several other ongoing…
-
The were ten updates to the TAG listing in July 2025. New Additions Four newly registered HIV cure-related studies were added: Oxford University in the UK is sponsoring AbVax, a phase II combination trial that will administer therapeutic vaccines designed to induce T cell responses against HIV plus two broadly neutralizing antibodies (bNAbs), teropavimab…
-
IAS 2025, the 13th IAS Conference on HIV Science, is taking place in Kigali, Rwanda from July 14-17, with several pre-conference events scheduled on Sunday July 13. In many cases remote access will also be possible for registered attendees, with recordings made publicly available two months after the meeting ends. Links to events and sessions…
-
The June 2025 update to TAG’s listing features 11 changes. New Additions Two studies were added: The ACTG has registered a new trial of dual broadly neutralizing antibodies (bNAbs), VRC07-523LS and PGT121.414.LS, in people who initiated antiretroviral therapy (ART) during acute HIV infection. The protocol includes an analytical treatment interruption (ATI) to assess whether receipt…
-
For March, April, and May 2025, there were 38 updates to entries in TAG’s listing. The majority involved the addition of links to results presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. As is covered further below, this period has seen a horrific and unprecedented political attack on scientific…
-
For February 2025, there were eight updates to TAG’s listing. New Additions Four new protocols were added. In Toronto, a trial is underway that aims to assess whether the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz may be able to promote the death of HIV-infected cells. The rationale derives from evidence that certain NNRTI molecules can…
-
For January 2025 there were only two updates to TAG’s listing, likely reflecting the holiday period since the December update. New Links to Study Results Both updates were links to newly available results from studies in the listing. At the HIV Persistence Workshop last December in Fort Lauderdale, James McMahon and colleagues presented preliminary information…
-
For December 2024, there were seven updates to TAG’s listing. New Additions The lone addition this month is a clinical trial sponsored by the ACTG investigating the capacity of a therapeutic vaccine to promote neutralizing antibody responses against HIV. The vaccine contains a stabilized part of the outer HIV envelope designed to mimic the natural…
-
For November 2024, there were 11 updates to TAG’s listing. We’ve also added the country locations for each of the current trials (previously, site locations were only included in the table in our annual Research Toward a Cure and Immune-Based Therapies Pipeline Report). New Additions Four new clinical trials were identified in registries: Researchers in…
-
There were 14 updates to TAG’s listing for October 2024. New Additions Two new clinical trials were identified in registries, neither yet open for enrollment: Researchers in the UK are initiating a study of the anti-CMV drug letermovir primarily to assess effects on T cell activation in people with HIV on antiretroviral therapy (ART). Markers…